Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 16/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.69 |
| ▸ | HPGD | P15428 | 11/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CASP1 | P29466 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24477299 | 0.84 | ALDH1A1 (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL9901617 | 0.82 | ALDH1A1 (1.00) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL24477300 | 0.78 | ALDH1A1 (0.72) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL22767493 | 0.78 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL9926700 | 0.77 | HPGD (0.78) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL9926694 | 0.77 | KDM4E (0.72) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL22767521 | 0.76 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL23015456 | 0.76 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL1006755 | 0.76 | KDM4E (0.70) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 | |
| SCHEMBL17739834 | 0.76 | GBA1 (0.63) | KDM4EALDH1A1HPGDHSD17B10CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | claimed |
| EP-3366688-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2022-02-09 | — | — | EP | disclosed |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20180263988-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2018-09-20 | — | — | US | disclosed |
| EP-3366688-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| EP-2649075-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2649075-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2012078855-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263988-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885ALDH1A1 2433/4885HPGD 2444/4885 |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885ALDH1A1 2433/4885HPGD 2444/4885 |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885ALDH1A1 2433/4885HPGD 2444/4885 |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | GBA1, GAA, GBA3 | KDM4E 2174/4885ALDH1A1 2433/4885HPGD 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.